Experimental

General remarks
Starting materials and reagents were purchased from Sigma Aldrich, TCI, Fluka and used as received. N-Methyl-2-pyrrolidone (NMP) for oligomer synthesis was obtained from Carl Roth GmbH and used without additional purification. Fmoc-(R,R)-ACHC-OH was prepared as described in literature [S1]. Fmoc-β-HLys(Z)-OH was obtained by the Arndt-Eistert homologation of the respective α-amino acid [S2] . Fmoc-Sieber amide resin for SPPS was purchased from Novabiochem (Merck) and stored at 4 C.
The 20% ammonia solution in ethanol was prepared by condensing 10 mL ammonia in 40 mL EtOH at −40 C. Before opening, chemicals were warmed to room temperature. Analytical thin-layer chromatography (TLC) was performed on silica gel precoated aluminum sheets from Merck (silica gel 60-F 254 , layer thickness 0.25 mm) and detected under UV lamp or by developing with 2,4-dinitrophenylhydrazine (2,4-DNP) solution or I 2 . Flash column chromatography was performed on Merck silica gel 60 (40-60 μm) at 0.3 to 1.1 bar pressure. The solvents for flash column chromatography were distilled prior to use. For HPLC analysis CH 3 CN (HPLC grade) and ultra pure H 2 O (Millipore, Bedford, UK) were used. Melting points were obtained with a Bibby-SMP10 melting point apparatus and are uncorrected. Optical rotations were measured on a Perkin-Elmer 241 polarimeter. IR spectra were recorded on a Digilab Excalibur FTIR spectrometer. 1 H and 13 C NMR spectra were recorded at 298 K in deuterated solvents using Bruker Avance 300/500 MHz spectrometers. Mass spectra (ESI-MS) were recorded on a Finnigan LCQ mass spectrometer. Highresolution mass spectra (HRMS-ESI) were obtained with the Bruker Apex-Q IV FT-ICR mass spectrometer. CD spectra were recorded on a JASCO J-810 spectrometer equipped with a JASCO ETC-505S/PTC-423S temperature controller. HPLC analysis S3 and purification of the oligomers was performed on a Pharmacia Äkta Basic system (GE Healthcare, London, UK) with a pump type P-900, variable wavelength detector UV-900 using C18 MN-Nucleodur 100-5 C-18 (250 × 4.6 mm, 5 m) analytical HPLC column. All HPLC runs were performed by using a linear gradient of A (0.1% aq TFA) and B (80% aq CH 3 CN and 0.1% TFA). Flow rates were taken as 1 mL min 1 for the analytical HPLC. For HPLC, glycoconjugates were dissolved in Milli Q H 2 O. All sample solutions were filtered prior to injection. UV detection was conducted at 215
nm. All CD measurements were carried out at 20 M peptide concentration in 5 mM triethylammonium acetate buffer (pH 7.0) with a quartz cell of 1 cm path length.
Spectra represent the average of 6 scans after baseline correction. 3, 41.0, 47.0, 55.2, 60.5, 72.5, 73.4, 74.8, 75.6, 77.1, 79.9, 82.2, 98.2, 127.5, 127.7, 127.8, 127.9, 128.0, 128.1, 128.3, 128.4, 138.1, 138.2, 138.8, 172 2, 37.0, 48.5, 55.2, 60.4, 73.3, 73.5, 74.6, 75.7, 78.5, 80.1, 82.3, 97.7, 127.5, 127.7, 127.8, 127.9, 128.0, 128.1, 128.3, 128.4, 137.7, 137.9, 138.5, 172.4 55.4, 70.2, 73.3, 74.2, 75.5, 75.7, 79.8, 82.1, 97.9, 127.6, 127.8, 127.9, 128.1, 128.3, 128.4, 128.5, 137.6, 137. 48.8, 55.9, 69.5, 73.2, 74.4, 75.6, 77.0, 79.9, 81.9, 97.9, S6 127.6, 127.7, 127.9, 128.1, 128.2, 128.3, 128.4 128.5, 137.2, 137.8, 138.3, 175 and NaHCO 3 (0.97 g, 11.5 mmol) were added. The turbid reaction mixture was stirred at 0 °C for 1 h and then stirred at room temperature overnight. 5, 46.8, 47.3, 55.5, 66.6, 71.2, 73.4, 75.4, 75.8, 77.8, 79.7, 81.7, 98.1, 119.8, 120.9, 124.9, 125.0, 127.0, 127.1, 127.6, 127.7, 127.8, 127.9, 128.0, 128.1, 128.3, 128.4, 128.5, 137.9, 138.0, 138.5, 141.2, 143.6, 143.8, 155.7 (C=O) 3, 25.0, 25.9, 26.0, 35.5, 47.2, 48.9, 66.7, 66.8, 70.6, 71.1, 71.7, 96.5, 108.8, 109.5, 119.8, 125.1, 126.9, 127.5, 141.1, 141.2, 143.8, 143.9, 156 
Synthesis of compounds
Ethyl (methyl 1,2:3,4-di-O-isopropylidene-6-amino-6,7-dideoxy-L-glycero--D-
galacto-octo-pyranoside)uronate (10c
General procedure for solid-phase β-glycopeptide synthesis
Oligomers were prepared in a similar manner as described in reference [S3] by manual solid-phase peptide synthesis in a 2 mL BD syringe, using a Fmoc-Sieber amide resin with a loading capacity of 0.61 mmol g
1
. For oligomer syntheses a resin preloaded with H-β-HGly-OH (40.0 mg resin, 25 µmol homoglycine amide) was used.
For peptide bond formation double coupling of the amino acids at 50 °C was needed.
First, an excess of 5 equivalents amino acid (125.0 µmol) was used, activated by O- (2 mL), the following procedure was carried out for each coupling step:
1. Fmoc-deprotection twice, 10 min with 20% piperidine in NMP (2 mL) 2. Washing four times with NMP (2 mL), then four times with CH 2 Cl 2 (2 mL) and four times with NMP (2 mL) S10 3. Double coupling steps, each 1.5 h with gentle moving at 50 °C 4. Washing with NMP (3 × 2 mL), CH 2 Cl 2 (3 × 2 mL), and NMP (3 × 2 mL);
5. Capping twice for 3 min with NMP/Ac 2 O/DIPEA (8:1:1, 2 mL).
6. After the final coupling cycle, N-terminal Fmoc group was deprotected and resin washed with NMP (4 × 2 mL), DCM (4 × 2 mL), NMP (4 × 2 mL), MeOH (4 × 2 mL), DCM (4 × 2 mL) and dried overnight in vacuo.
TFA cleavage and deprotection:
The glycopeptide species were selectively cleaved from the solid support under acidic conditions using 5% TFA in dry CH 2 Cl 2 . Cleavage reactions were carried out for 1 h, shaking at ambient temperature. The reaction mixture was neutralized by filtering it in 10% pyridine in CH 2 Cl 2 and washing with 
Crystallographic data of compound 10b
ORTEP diagram of compound 10b.
Crystal structure determination:
The crystal structure of 10b was determined using single-crystal X-ray crystallography at 100 K. The crystal was desiccated, split and pseudomerohedrally twinned. The twin fraction refined to 0.335. Diffraction data were measured using Cu Kα radiation from a rotating anode source on a SMART 6000 CCD area detector mounted on a Bruker three-circle diffractometer. Integration was done using SAINT
[S4], absorption correction and scaling using SADABS [S5] , space group determination and data reduction using XPREP [S4]. The structure was solved using direct methods as implemented in SHELXT, with four molecules in the asymmetric unit, two of which are partly disordered. Full-matrix least-squares refinement against F 2 was performed using SHELXL-2013 [S6], using RIGU [S7] and SADI restraints for the disordered parts. Model building was done using SHELXLE [S8] . Absolute structure was determined using Parsons´s method S9, with the Flack parameter refining to a value of 0.001(41). 
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